Presentation: Delivering on the Promise of Targeted Protein Degradation: A Roadmap to Patient Impact

Session details:

Targeted protein degradation (TPD) has emerged as a transformative therapeutic modality, capable of eliminating disease-causing proteins once deemed “undruggable” by conventional approaches. Paige Mahaney, Ph.D., chief scientific officer at C4 Therapeutics, will share what lies ahead for the field, outlining both the clinical progress that has validated TPD’s mechanism and opportunities to overcome remaining challenges in development. She will also define the hallmarks of an effective degrader including thoughtful target selection, catalytic efficiency, optimization of drug-like properties, and achieving CNS exposures to potentially outperform small molecules. With ongoing innovation, TPD is positioned to deliver impact for patients across multiple therapeutic areas including cancer and autoimmunity.